title: AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.
abstract: The 21st international symposium of the American Association for Cancer Research (AACR), the NCI and the European Organization for Research and Treatment of Cancer (EORTC), held in Boston, included topics covering the development of therapeutics and molecular targets in the field of cancer research. This conference report highlights selected presentations on the development of novel drugs for cancer. Investigational drugs discussed include RO-506876 (F Hoffmann-La Roche Ltd), GDC-0980 (Genentech Inc), EMD-1214063 and EMD-1204831 (Merck Serono SA), AR-mTOR01 and AR-mTOR-26 (Array BioPharma Inc), GSK-2126458 (GlaxoSmithKline plc), EXEL-1415 and EXEL-2008 (Exelixis Inc), FP-1039 (FivePrime Therapeutics Inc), and AV-412 (AVEO Pharmaceuticals Inc).
authors.affiliation: Thomson Reuters, 77 Hatton Garden, London EC1N 8JS, UK. karen.walker@thomsonreuters.com
authors.forename: Karen
authors.initials: K
authors.lastname: Walker
authors.forename: Meenal
authors.initials: M
authors.lastname: Padhiar
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational